{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc:tafinlar:1 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahc%3Atafinlar%3A1",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001625,
    "timestamp_received": "2026-09-25T00:12:03.384535+00:00Z",
    "timestamp_returned": "2026-09-25T00:12:03.386160+00:00Z",
    "trace_id": "34491bd8-29a2-4bb9-b5cf-9a643f9b3d2f"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "ind:hc:tafinlar:1",
      "type": "Indication",
      "description": "TAFINLAR (dabrafenib mesylate), in combination with trametinib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.",
      "contributions": [],
      "reportedIn": [
        {
          "id": "doc:hc:tafinlar",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tafinlar (dabrafenib) [product monograph]. HC.",
          "title": null,
          "aliases": [],
          "description": "Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083523.PDF. Revised February 2026. Accessed April 2026.",
          "urls": [
            "https://pdf.hres.ca/dpd_pm/00083523.PDF",
            "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hc",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Canada",
                "description": "Regulatory agency that approves drugs for sale and use in Canada."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Novartis Pharmaceuticals Canada Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tafinlar",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "dabrafenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2013-08-23",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2026-02-16",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        }
      ]
    }
  ]
}